Sorrento Therapeutics
(OTC) SRNE
Sorrento Therapeutics Financials at a Glance
Market Cap
$1.76M
Revenue (TTM)
$64.27M
Net Income (TTM)
$549.21M
EPS (TTM)
$0.00
P/E Ratio
0.00
Dividend
$0.00
Beta (Volatility)
-0.35 (Low)
Dividend
$0.00
Beta (Volatility)
-0.35 (Low)
Price
$0.00
Volume
38,410
Open
$0.00
Price
$0.00
Volume
38,410
Open
$0.00
Previous Close
$0.00
Daily Range
$0.00 - $0.00
52-Week Range
$0.00 - $0.10
Dividend
$0.00
Beta (Volatility)
-0.35 (Low)
Price
$0.00
Volume
38,410
Open
$0.00
Previous Close
$0.00
Daily Range
$0.00 - $0.00
52-Week Range
$0.00 - $0.10
SRNE News
SRNE: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Sorrento Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
949
CEO
Henry H. Ji, PhD
Website
www.sorrentotherapeutics.comHeadquarters
San Diego, CA 92121, US
SRNE Financials
Key Financial Metrics (TTM)
Gross Margin
47%
Operating Margin
-8%
Net Income Margin
-9%
Return on Equity
0%
Return on Capital
-3%
Return on Assets
-1%
Earnings Yield
N/A
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$1.76M
Shares Outstanding
551.28M
Volume
38.41K
Short Interest
0.00%
Avg. Volume
107.98K
Financials (TTM)
Gross Profit
$29.39M
Operating Income
$504.31M
EBITDA
$539.93M
Operating Cash Flow
$293.86M
Capital Expenditure
$13.66M
Free Cash Flow
$307.51M
Cash & ST Invst.
$49.98M
Total Debt
$134.50M
Sorrento Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$15.03M
+31.1%
Gross Profit
$6.57M
+14.2%
Gross Margin
43.74%
N/A
Market Cap
$1.76M
N/A
Market Cap/Employee
$1.86K
N/A
Employees
949
N/A
Net Income
$95.21M
+56.6%
EBITDA
$99.48M
+53.5%
Quarterly Fundamentals
Net Cash
$126.97M
-50.2%
Accounts Receivable
$32.73M
+32.4%
Inventory
$9.65M
-53.4%
Long Term Debt
$74.19M
-55.7%
Short Term Debt
$133.41M
+163.0%
Return on Assets
-1.21%
N/A
Return on Invested Capital
-3.48%
N/A
Free Cash Flow
$55.80M
+33.3%
Operating Cash Flow
$55.66M
+31.3%